New Delhi, Dec 6 (PTI) Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator to market its generic Varenicline tablets indicated for use as an aid to smoking cessation treatment.

The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Varenicline tablets of strengths 0.5 mg and 1 mg, Lupin said in a regulatory filing.

Also Read | Dr BR Ambedkar Death Anniversary 2023: Here Are Some Key Facts About Chief Architect of Indian Constitution on Mahaparinirvan Diwas.

These are the generic equivalents of Chantix tablets, 0.5 mg and 1 mg, of PF Prism CV.

"The product will be manufactured at Lupin's Pithampur facility in India," the company said.

Also Read | CAT 2023 Exam: Response Sheet of Common Admission Test Examination Released at iimcat.ac.in, Raise Objections Till December 8.

Varenicline tablets, 0.5 mg and 1 mg, are indicated for use as an aid to smoking cessation treatment, it added.

Varenicline tablets had estimated annual sales of USD 430 million in the US, the company said, citing IQVIA MAT October 2023 data.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)